ADVERTISEMENT

Coronil gets Ayush Ministry certification as 'supporting measure' for COVID-19 treatment

February 19, 2021 01:17 pm | Updated 01:35 pm IST - New Delhi

The medicine was launched at an event which was presided by Union Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari.

A photo of the kit released by Patanjali on Twitter.

Haridwar-based Patanjali Ayurved on Friday said Coronil has now received certification from Ayush Ministry as per World Health Organization (WHO) certification scheme.

The company claimed that it is the first evidence-based medicine to fight COVID-19.

The medicine was launched here at an event which was presided by Union Health Minister Harsh Vardhan and Transport Minister Nitin Gadkari.

ADVERTISEMENT

"Coronil has received the Certificate of Pharmaceutical Product (CoPP) from the Ayush section of Central Drugs Standard Control Organisation as per the WHO certification scheme," said Patanjali in a statement.

Under CoPP, Coronil can now be exported to 158 countries.

Commenting of the development Swami Ramdev said, Coronil will help the humanity while providing affordable treatment based on naturopathy.

ADVERTISEMENT

On the basis of presented data, the Ministry of Ayush has recognised Coronil Tablet as a medicine for "supporting measure in COVID-19." Patanjali had earlier introduced Ayurveda-based Coronil on June 23 last year, when the pandemic was at its peak.

However, it had to face severe criticism as it lacked scientific evidence.

Then, the Ayush Ministry had indicated it as "Immuno-booster" only.

Coronil is developed by Patanjali Research Institute. It had started work for an Ayurvedic remedy for COVID-19 in January, 2020.

This is a Premium article available exclusively to our subscribers. To read 250+ such premium articles every month
You have exhausted your free article limit.
Please support quality journalism.
You have exhausted your free article limit.
Please support quality journalism.
The Hindu operates by its editorial values to provide you quality journalism.
This is your last free article.

ADVERTISEMENT

ADVERTISEMENT